Exaggerated benefit found in 1 out of 3 early trials


READ MORE

This is an excerpt from Second Opinion, a weekly roundup of eclectic and under-the-radar health and medical science news emailed to subscribers every Saturday morning. If you haven’t subscribed yet, you can do that by clicking here.


A new drug or medical device might show a promising benefit in the first trial, and even in the second trial. But for some mysterious reason that treatment effect can get smaller in followup studies.


“In reality, it shouldn’t,” said Dr. Hassan Murad, a Mayo Clinic epidemiologist and author of a new study on the vanishing treatment effect. “If everything is at random, you should expect that the earlier study or the later study should show an effect that is similar.”


Murad’s study compared results from more than 900 trials for drugs and devices to treat chronic medical conditions including cancer, diabetes, high blood pressure and heart disease. The researchers found that in about a third of the studies, an early benefit faded over time.


“We were surprised at the prevalence,” said Murad, adding that it means one out of every three studies could show a benefit that won’t show up in later studies.


The vanishing benefit is called the “Proteus Effect,” named for a shape-shifting character from Greek mythology. And there’s no way to tell which one out of three new studies will be the one where the benefit fades over time.


Unintentional bias?


“We tried to see if perhaps the size of the study matters, or how well the study was done, or whether it was a multi-centre versus single-centre. We tried to look at several explanations that would explain this, and we couldn’t find any explanation.”


Murad said one possible explanation might be that people who are chosen for the first trials are healthier, with fewer complications, a bias that might be unintentional.



  • Should we let the crowd fund Canadian science if no one else will?


  • How many new drugs rely on government-funded science? All of them


“They will choose patients that are more likely to benefit.” Murad said. “Whereas in subsequent trials, they choose everyone. That’s like the real-world experience in subsequent trials.”


The first trials also get the most publicity. And Murad said people are often eager to use the newest drugs.


“And unfortunately [with] the subsequent trials, sometimes people don’t hear about them, because the results are not as impressive, and because the practice has already shifted.”



To read the entire Second Opinion newsletter every Saturday morning, subscribe by clicking here.


Article source: http://www.cbc.ca/news/politics/bloc-quebecois-ouellet-1.4555185?cmp=rss


Best Wordpress Plugin development company in India     Best Web development company in India

Comments

Post a Comment

Popular posts from this blog

Canadian expected to be aboard Russia's 1st manned space mission since rocket failure

READ MORE The first manned mission to the International Space Station since a Russian rocket failed to launch successfully earlier this month may take off on Dec. 3, space agency Roscosmos said on Wednesday. And the crew is expected to include Canadian astronaut David Saint-Jacques, Agence France-Press reported. A Russian cosmonaut and U.S. astronaut were forced to abort their mission on Oct. 11 and perform an emergency landing after a launch accident that Roscomos said was caused by a faulty sensor. The accident was the first serious launch problem experienced by a manned Soyuz space mission since 1983, when a crew narrowly escaped before a launch pad explosion. Sergei Krikalyov, a senior Roscosmos official, was quoted by state news agency Tass as saying the next manned launch had been planned for mid-December, but that Russia was trying to bring the date forward so that the ISS is not briefly left without a crew. “The industry is making significant efforts to move the launch t...
Read more

Getting the dope on pot stocks is becoming easier as media groups invest in content: Don Pittis

Image
READ MORE “What’s the buzz? Tell me what’s happening,” goes the ’70s rock anthem. Part of the catchiness of the lyric — from the rock musical Jesus Christ Superstar  — was that in that era the term “buzz” had developed a second spicy meaning. It described the high that people got from smoking cannabis. In the 1970s, the magazine High Times was a brand new title keeping an eye on the illegal but growing business of marijuana pricing and sales. It ran centrefolds of glistening pot plants and of an apartment filled to the windows with what the magazine insisted was an entire ton of cannabis. Now some of Canada’s most staid media voices are looking for ways to go toe to toe with High Times and its U.S. competitors, hoping to profit from Canada’s global head start in legal recreational cannabis. But when it comes to making a killing from spreading the buzz on the cannabis biz, to q...
Read more

Toronto man denies conspiring with Marvel CEO in alleged hate mail scheme

Image
READ MORE A Toronto man accused of conspiring with the head of Marvel Entertainment in a bizarre hate mail campaign against his wealthy former employer has denied any role in the alleged scheme. David Smith, along with Marvel CEO Isaac (Ike) Perlmutter, is the target of a slander lawsuit launched earlier this year by Canadian businessman Harold Peerenboom. Now Smith — a former employee of Peerenboom’s Toronto-based executive search firm, Mandrake Management — has filed a motion to dismiss the U.S. civil suit. It’s the latest development in the years-long legal battle between Peerenboom and Perlmutter, a notoriously reclusive American billionaire and personal friend of U.S. President Donald Trump. The hate mail campaign, which ran   between 2012 to 2015, saw anonymous letters falsely accusing Peerenboom of being a child molester, murderer and anti-Semite...
Read more